Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $16.90 USD
Change Today +0.16 / 0.96%
Volume 1.7K
IPSEY On Other Exchanges
EN Paris
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

ipsen sa-sponsored adr (IPSEY) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/21/15 - $17.30
52 Week Low
10/16/14 - $10.77
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IPSEN SA-SPONSORED ADR (IPSEY)

Related News

No related news articles were found.

ipsen sa-sponsored adr (IPSEY) Related Businessweek News

View More BusinessWeek News

ipsen sa-sponsored adr (IPSEY) Details

Ipsen S.A. operates as a pharmaceutical company worldwide. It operates through two segments, Primary Care and Specialty Care. The company offers drugs in uro-oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and cardiovascular areas. Its products include Decapeptyl, a peptide formulation for injection for the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline, which is used primarily in the treatment of acromegaly and neuroendocrine tumors. The company also provides NutropinAq, a liquid formulation for use in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it offers Smecta, a natural clay-based drug for use in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan, an oral formulation, which is used for the treatment of age-related cognitive disorders. Further, the company provides Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl products. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

4,500 Employees
Last Reported Date: 07/31/15
Founded in 1929

ipsen sa-sponsored adr (IPSEY) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: €1.8M
Deputy Chief Executive Officer
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2014.

ipsen sa-sponsored adr (IPSEY) Key Developments

Ipsen Launches Manufacturing Facility in Russia with Group ROSTA

Ipsen announced the launch of a manufacturing site at Raduga Production in St Petersburg which is part of Group ROSTA. As per the company, the production of cognitive-disorders drug Tanakan (ginkgo biloba extract) is to be established there, as part of a joint project between the parties, with capacity being approximately 120 million tablets per year.

Ipsen S.A. Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015; Raises Earnings Guidance for the Year 2015

Ipsen S.A. announced unaudited consolidated earnings results for the six months ended June 30, 2015. For the period, the company reported sales of EUR 713.9 million against EUR 638.7 million a year ago. Revenues were EUR 751.9 million against EUR 668.8 million a year ago. Core operating income was EUR 167.6 million against EUR 162.0 million a year ago. Operating income was EUR 103.4 million against EUR 146.3 million a year ago. Net profit from continuing operations was EUR 90.2 million against EUR 104.7 million a year ago. Consolidated net profit attributable to shareholders of the company was EUR 90.1 million against EUR 104. a year ago. Earnings per share fully diluted share were EUR 1.09 against EUR 1.26 a year ago. Core earnings per share fully diluted was EUR 1.50 against EUR 1.40 a year ago. Net cash provided by operating activities was EUR 36.2 million against EUR 54.7 million a year ago. Acquisition of property, plant & equipment was EUR 16.4 million against EUR 20.9 million a year ago. Acquisition of intangible assets for EUR 5.4 million, compared with EUR 3.3 million in the first half 2014. Core operating income was up 3.5%, in view of the investment in neuroendocrine tumors. Net operating cash-flow driven by an increase of the working capital requirement for operating activities of EUR 106.8 million in the first half 2015, compared to an increase of EUR 73.3 million in the first half 2014. The company revised earnings guidance for the year 2015. The group expects sales to grow above 9.5%. Upgrade of the Core operating margin guidance at or above 22.0% of group sales, reflecting the growth of specialty care and the investments required to support the global launch of Somatuline® and that of Dysport® in the US.

Ipsen S.A., H1 2015 Earnings Call, Jul 31, 2015

Ipsen S.A., H1 2015 Earnings Call, Jul 31, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPSEY:US $16.90 USD +0.16

IPSEY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Daiichi Sankyo Co Ltd ¥2,310 JPY +57.00
H Lundbeck A/S kr209.20 DKK -0.80
View Industry Companies

Industry Analysis


Industry Average

Valuation IPSEY Industry Range
Price/Earnings 35.8x
Price/Sales 3.5x
Price/Book 4.4x
Price/Cash Flow 36.1x
TEV/Sales 3.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IPSEN SA-SPONSORED ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at